Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening

Inclusion Criteria: * Eligible women will include resident women born between 1994-1999 (1993-1999 in the non intervention arm), who have not opted out of the screening program and who consent to participate in the study. Exclusion Criteria: * Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate * Known history of immune-related disorders * Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever. * Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose * Current pregnancy (reported) * Women with a total hysterectomy